HDAC9 and kidney disorder: HDAC inhibitors have shown to be effective in reducing the pathogenesis in pre-clinical models of several kidney diseases including, glomerulosclerosis, tubulointerstitial fibrosis, lupus nephritis, polycystic kidney disease, renal injury and diabetic Nephropathy [4,182].